HIV-1 subtype C, tenofovir, and the relationship with treatment failure and drug resistance by Günthard, Huldrych F & Scherrer, Alexandra U
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
HIV-1 subtype C, tenofovir, and the relationship with treatment failure and
drug resistance
Günthard, Huldrych F; Scherrer, Alexandra U
DOI: https://doi.org/10.1093/infdis/jiw214
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-132471
Published Version
 
 
Originally published at:
Günthard, Huldrych F; Scherrer, Alexandra U (2016). HIV-1 subtype C, tenofovir, and the relationship
with treatment failure and drug resistance. Journal of Infectious Diseases, 214(9):1289-1291.
DOI: https://doi.org/10.1093/infdis/jiw214
The Journal of Infectious Diseases
E D I T O R I A L C O M M E N T A R Y
HIV-1 Subtype C, Tenofovir, and the Relationship With
Treatment Failure and Drug Resistance
Huldrych F. Günthard and Alexandra U. Scherrer
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich and Institute of Medical Virology, Switzerland
(See the major article by White et al on pages 1302–8.)
Keywords. HIV-1; drug resistance; subtype c; tenofovir; treatment failure; antiretroviral treatment.
Tenofovir disoproxil fumarate (TDF) has
emerged as a cornerstone of initial antire-
troviral therapy (ART) [1, 2]. However,
human immunodeﬁciency virus type 1
(HIV) subtype C, the most prevalent
worldwide subtype, accounting for >50%
of all HIV infections, harbors polymor-
phisms in reverse transcriptase codons
64, 65, and 66, which lead to more-rapid
in vitro selection of the K65R mutation
[3], the signature mutation conferring re-
sistance to TDF [4]. Subtype C viruses
may only require a single point mutation
at position 65 to select for K65R. Several
clinical studies have suggested that this
mechanism may contribute to higher
treatment failure rates and higher rates
of the emergence of the K65R mutations
observed in HIV subtype C–infected,
compared with subtype B–infected, indi-
viduals treated with TDF-containing reg-
imens [5–9], although others could not
conﬁrm different response rates between
subtype B and C [10–12].
In this issue of The Journal of Infec-
tious Diseases, White et al report a
comprehensive study on this issue [13].
They analyzed data from the UK Collab-
orative HIV Cohort (CHIC) Study (avail-
able at: http://www.ukchic.org.uk) and
included 8746 patients who had initiated
ART containing TDF, plus lamivudine or
emtricitabine and either a nonnucleoside
reverse transcriptase inhibitor (NNRTI;
efavirenz or nevirapine) or a ritonavir-
boosted protease inhibitor (lopinavir, ata-
zanavir, or darunavir), and were followed
for a median of 3.3 years. Unadjusted anal-
yses indicated an approximately 2-fold
higher virological failure rate for subtype
C–infected individuals as compared to
subtype B–infected individuals. However,
when they adjusted for demographic and
clinical factors, no differences in treatment
response between subtype C– and subtype
B–infected patients was seen. The analysis
of emerging resistance showed that in pa-
tients who failed treatment, the K65R mu-
tation occurred signiﬁcantly more often in
subtype C than in B or non B/C infected
individuals. The authors concluded from
their analysis that there is no intrinsic effect
of viral subtype C on the efﬁcacy of teno-
fovir-containing ﬁrst-line regimens.
A strength of the UK CHIC study is that
it only analyzed TDF-containing ﬁrst-line
regimens, that they had large absolute num-
bers of subtype B– and subtype C–infected
patients obtaining these ﬁrst-line regimens,
and that the study was conducted in a single
large national health system where all HIV-
infected patients have similar access to ART
and care. The clinical and demographic
data available allowed them to adjust for
potential confounding factors such as
ethnicity, which may be associated with ad-
herence to therapy, baseline viral load, base-
line CD4+ T-cell count, time of enrollment,
and transmission groups.
Why is it that some previous studies dem-
onstrated increased failure and resistance
rates in subtype C– as compared to subtype
B–infected patients treated with TDF [5–9]?
Themajor factor explaining these discrepan-
cies most likely is confounding by adherence
or continuous access to treatment, which
wasmore difﬁcult to adjust for in other stud-
ies that were performed across various coun-
tries and healthcare systems. Within the
same healthcare system, it has been shown
that black ethnicity of sub-Saharan origin
was associated with higher treatment failure
rates, compared with white or Asian ethnic-
ities [14, 15]. In addition, among patients
treated in resource-limited settings, detec-
tion of viral failure is often delayed because
of lack of viral monitoring [8, 16], and in
some studies deﬁnition of viral load failure
was set considerably higher (eg, >1000
HIV RNA copies/mL or 2 consecutive
viral loads of >1000 HIV RNA copies/mL)
[6, 7], when compared to those used by
White et al (2 consecutive viral loads of
>200 HIV RNA copies/mL). This means
that in the previous studies, replicating virus-
es were exposed to the selection pressure ex-
erted by TDF for longer periods and, thus,
that the chance to acquire the K65R muta-
tion was higher. Another potential factor ex-
plaining differences may be that White et al
looked at relatively modern treatments: the
median year of ART initiation was 2008
for subtype B–infected subjects and 2009
for subtype C–infected subjects, and 70.2%
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and 66.3% of the treatments, respectively,
consisted of EFV + TDF + FTC or 3TC.
Most likely, the majority of these regimens
consisted of coformulated TDF and FTC
(Truvada), although this was not speciﬁed
in the article. It has previously been shown
that NNRTI-containing regimens including
TDF and 3TC showed higher rates of treat-
ment failure and resistance when compared
to TDF/FTC-containing regimens [17, 18],
although if corrected for pill burden and
ethnicity, the differences between the 2 nu-
cleoside reverse transcriptase inhibitor back-
bones waned [14, 18]. Potentially, 3TC was
more often used in resource-limited settings
than in the UK-CHIC analysis. We can
speculate that, in treatments consisting of
drugs with a lower barrier to virological fail-
ure and resistance, subtype C infection can
have an impact on treatment outcome. A
paradox, however, persists: if patients infect-
ed with subtype C do not respond to treat-
ment, the likelihood is higher to select for
the K65R mutation, as also shown by
White et al, even though no differences in
failure rates were observed when compared
to patients infected with subtype B. An ex-
planation for this phenomenon could be
that, in an optimal treatment setting, treat-
ment response is not affected by the single
point mutation. However, if adherence or
the other factors mentioned above are sub-
optimal, then the mutation occurs much
faster in subtype C than in subtype B. Fur-
ther studies in well-controlled settings will
be needed to elucidate this phenomenon.
The study by White et al provides reas-
surance that TDF-containing therapies
also work well in subtype C–infected pa-
tients starting ﬁrst-line NNRTI-based
ART and that, currently, no change in rec-
ommendations regarding ART for HIV
subtype C is warranted. This also should
not change when the less toxic nucleotide
reverse transcriptase inhibitor tenofovir
alafenamide likely replaces TDF as part of
initial regimens, because the mechanism of
resistance of the 2 drugs is the same [19].
However, rates of transmitted drug resis-
tance in all parts of the world need to be
monitored closely, since recent reports
suggest considerable increases of NNRTI-
based transmitted drug resistance, such as
in sub-Saharan Africa [20], where HIV
prevalence is highest and availability of dif-
ferent drug classes still limited.
The major message from lower treat-
ment responses that have been reported
in some studies among subtype C–infected
individuals is that, as White et al show, this
is not primarily a result of a single nucleo-
tide change leading to the K65R mutation,
but rather because treatment conditions in
studies conducted in resource-rich and re-
source-limited settings were different. For
these reasons, it is of utmost importance
to globally improve treatment conditions
so that adherence problems and treatment
failures can be identiﬁed early, most im-
portantly through viral load monitoring,
optimally every 3–6 months [1], or that
strategies such as the recently proposed
viral-load-informed differentiated care
[21] are also adopted.
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